Effects of sorafenib on symptoms and quality of life: Results from a large randomized placebo-controlled study in renal cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 30, Issue 3, 2007, Pages 220-227

  Bukowski, Ronald ^a   Cella, David ^b   Gondek, Kathleen ^c   Escudier, Bernard ^d  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b EVANSTON NORTHWESTERN HEALTHCARE   (United States)

^c BAYER CORPORATION   (United States)

^d INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Kidney cancer; Quality of life; Renal cell cancer; Sorafenib; Symptoms

Indexed keywords

PLACEBO; SORAFENIB;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; COUGHING; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FEMALE; FEVER; FUNCTIONAL ASSESSMENT; HEALTH SURVEY; HUMAN; KIDNEY CANCER; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PREDICTION; PROPORTIONAL HAZARDS MODEL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; STATISTICAL ANALYSIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PYRIDINES; QUALITY OF LIFE; SURVIVAL ANALYSIS;

EID: 34250026980     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/01.coc.0000258732.80710.05     Document Type: Article

References (18)

1. National Cancer Institute Plans and Priorities for Cancer Research. Available from: http://plan2004. cancer.gov/public/quality.htm.
2. American Cancer Society; Cancer Facts and Figures 2003. 2003.
3. Murphy GP, Lawrence W Jr, Lenhard RE. American Cancer Society Textbook of Clinical Oncology, 2nd ed. Atlanta, GA: American Cancer Society, 1995:635-654.
4. Victorson D, Soni M, Cella D. Meta analysis of the correlation between radiographic tumor response and patient-reported outcomes. Cancer. 2006;106:494-504.
5. Coons SJ, Kaplan RM. Assessing health-related quality of life: application to drug therapy. Clin Ther. 1992;14:850-858; discussion 849.
6. Glaspy JA. Therapeutic options in the management of renal cell carcinoma. Semin Oncol. 2002;29(suppl 7):41-46.
7. Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol. 2004;22:454-463.
8. Fish LS, Lewis BE. Quality of life issues in the management of ovarian cancer. Semin Oncol. 1999;26(suppl 1):32-39.
9. Committee for Medicinal Products for Human Use. Reflection Paper on the Regulatory Guidance for the Use of Health Related Quality of Life (HRQL) Measures in the Evaluation of Medicinal Products. Committee for Medicinal Products for Human Use, 2004.
10. Szende A, Leidy NK, Revicki D. Health-related quality of life and other patient-reported outcomes in the European centralized drug regulatory process: a review of guidance documents and performed authorizations of medicinal products 1995 to 2003. Value Health. 2005;8:534-548.
11. Cella D, Yount S, Hongyan D, et al. Development and validation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI). J Support Oncol. 2006;4:191-199.
12. Eisen T, Bukowski RM, Staehler S, et al. Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC): impact of crossover on survival. J Clin Oncol. 2006;24(suppl 18):4524.
13. Escudier B, Szczylik C, Eisen, et al. Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). J Clin Oncol. 2005;23(suppl 16):4510.
14. Cella D. FACIT Manual: Manual of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, Version 4. Evanston, IL: Center on Outcomes Research and Education (CORE), 2005.
15. Webster K, Cella D, Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation. Health Qual Life Outcomes. 2003;1:79.
16. Sutherland HJ, Lockwood GA, Boyd NF. Ratings of the importance of quality of life variables: therapeutic implications for patients with metastatic breast cancer. J Clin Epidemiol. 1990;43:661-666.
17. Chawla A, Holgrem E, Nelson B, et al. Impact of bevacizumab plus 5-FU/LV with or without irinotecan on quality of life in patients with metastatic colorectal cancer. In: Paris: The ECCO Book; 2005.
18. Escudier B, Eisen T, Stadler WM, et al. Sorafenib for advanced clearcell renal cell carcinoma. Global Evaluation Trial (TARGETs): a randomized, double-blind, placebo-controlled phase III trial of sorafenib, an oral multi-kinase inhibitor in advanced renal cell carcinoma. N Engl J Med. 2007;356:185-187.